Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (cGMP) quality control. Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients. Source
No articles found.
resTORbio, Inc. is a clinical-stage biopharmaceutical company developing innovativ...
resTORbio, Inc. is a clinical-stage biopharmace...
Grifols is a global healthcare company founded in Barcelona in 1909 committed to i...
Grifols is a global healthcare company founded ...
Fennec Pharmaceuticals, Inc., (NASDAQ: FENC; TSX: FRX) is a specialty pharmaceutic...
Fennec Pharmaceuticals, Inc., (NASDAQ: FENC; TS...
Iovance Biotherapeutics (formerly traded as Lion Biotechnologies) is focused on th...
Iovance Biotherapeutics (formerly traded as Lio...
Kazia Therapeutics is an oncology-focused biotechnology company, developing innova...
Kazia Therapeutics is an oncology-focused biote...
BioSculpture Technology, Inc. (âBSTâ) is a commercial-stage medical device man...
BioSculpture Technology, Inc. (âBSTâ) is a ...
Prevail Therapeutics is applying precision medicine to the development of gene the...
Prevail Therapeutics is applying precision medi...
Join the National Investor Network and get the latest information with your interests in mind.